跳到正文
WorldBrand.AI

阿拉宾度制药的争议事件

以下收录公开来源中与该品牌相关的争议事件。列出一条并不表示过错已经证实。

返回词条共 2 条

  1. 2020

    Aurobindo Pharma等因被指隐瞒二甲双胍污染而遭起诉

    提起诉讼

    MSP Recovery在美国法院对Aurobindo Pharma等药厂提起集体诉讼，指控其隐瞒二甲双胍含有致癌物NDMA的信息。报道称，Valisure的检测在Aurobindo及Heritage生产的二甲双胍中发现NDMA，但亦指出Aurobindo通过了FDA的NDMA检测。

    来源摘录

    • Valisures tests revealed that the metformin produced by Aurobindo and Heritage were contaminated with NDMA with levels between 37 and 266 ng per tablet.
    • A class action suit has been filed against some drug manufacturers, including Aurobindo Pharma Ltd. and Emcure Pharmaceuticals, in a U.S. court for allegedly concealing facts about a cancer-causing agent, N- nitrosodimethylamine presence in metformin medicine.
    • Florida-based law firm MSP Recovery filed the petition on April 3 in the U.S. District Court for the Southern District of Florida on behalf of similarly-situated healthcare insurers to recover payments unlawfully induced by the drug makers- Aurobindo Pharma, Aurolife Pharma, LLC, and Heritage Pharmaceuticals LLC.
    来源

  2. 2020

    Astellas 就专利侵权起诉多家制药公司

    提起诉讼

    Astellas Pharma Inc. 及关联原告在特拉华州起诉 21 家制药公司，指称其拟推出的 Myrbetriq 仿制药将侵犯 '780 专利。原告请求法院给予救济；相关内容属于诉状中的指称。

    来源摘录

    • At the District Court of Delaware on Tuesday, Astellas Pharma Inc. (API), Astellas Ireland Co. Ltd. (AICL), and Astellas Pharma Global Development (APGD) filed a complaint against 21 pharmaceutical companies alleging patent infringement.
    • The defendants are as follows: Sandoz Inc., Actavis Elizabeth LLC, Actavis LLC, Teva Pharmaceuticals USA Inc., Apotex Inc., Apotex Corp., Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc., Aurolife Pharma LLC, Sawai Pharmaceutical Co. Ltd., Sawai USA Inc., Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co. Ltd., Huahai US Inc., Solco Healthcare US LLC, Windlas Healthcare Pvt. Ltd., Windlas Biotech Ltd., Zydus Pharmaceuticals (USA) Inc., Cadila Healthcare Ltd. (doing business as Zydus Cadila), Lupin Ltd., and Lupin Pharmaceuticals, Inc.
    • The patent in question, deemed the ’780 patent, corresponds to APGD’s Myrbetriq extended-release tablets, containing active ingredient mirabegron, which is used to treat overactive bladder.
    来源